Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cagrilintide B and placebo semaglutide I
Cagrilintide B · 1 trial · 2 indications
Measured as hour\*nanomole per liter (h\*nmol/L).
Measured as nanomole per liter (nmol/L).
| Arm | Type | Description |
|---|---|---|
| Cagrilintide B | EXPERIMENTAL | Participants will receive cagrilintide B subcutaneously once weekly for 5 weeks. |
| Cagrilintide D | EXPERIMENTAL | Participants will receive cagrilintide D subcutaneously once weekly for 5 weeks. |
| Name | Type | Description |
|---|---|---|
| Cagrilintide B | DRUG | Cagrilintide B will be administered subcutaneously. |
| Cagrilintide D | DRUG | Cagrilintide D will be administered subcutaneously. |
Key Inclusion Criteria: * Age 18-64 years (both inclusive) at the time of signing informed consent. * Male or female (sex assigned at birth). * Body mass index (BMI) between 27.0 and 34.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose t...
Cagrilintide B is an investigational small molecule being studied for the treatment of overweight and obesity. It is currently in Phase 1 clinical development, with an active clinical trial evaluating its blood levels in adults with excess body weight.
Cagrilintide B is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in overweight and obese adults.
Cagrilintide B is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is active but not recruiting participants, with a planned enrollment of 50 adults.
Cagrilintide B is being studied in a Phase 1 clinical trial with the identifier NCT07605052. The trial, titled 'A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight,' is active but not recruiting and is being conducted in the United States.
Cagrilintide B is also known as Cagrilintide B and placebo semaglutide I. This alternative name may be used in clinical trial documentation to describe the study treatment regimen, which includes Cagrilintide B alongside a placebo for semaglutide.
Cagrilintide B is a peptide-based small molecule, classified under the target class '-tide (peptide).' It is being investigated for its effects on weight management, though the specific molecular target has not been disclosed in available information.